assign Low, Medium, or High-risk scores to each shipment route-product combination.

Step 2: Define Monitoring Strategy per Risk Tier:

Once tiers are defined, assign appropriate monitoring levels to each tier.

Example Monitoring Strategies:

• Low Risk: Stability studies show wide tolerance, passive packaging, monitor site storage only
• Medium Risk: Use data logger for select shipments, random audit-based checks
• High Risk: Real-time logger, shipment pre-alert, validated excursion response SOP

Reference tools and practices from Stability Studies to define product-specific thresholds.

Step 3: Select and Qualify Temperature Monitoring Devices:

Choose monitoring devices that align with risk tier expectations and regulatory requirements.

Device Requirements:

• Validated for accuracy and calibration traceability
• GxP-compliant software and secure data access
• Alarm configuration aligned to product stability
• Automatic upload of data to IRT or CTMS systems

Ensure qualification through IQ OQ PQ validation and document in the QMS.

Step 4: Develop Excursion Response SOPs:

Temperature excursions must be evaluated quickly to determine if the product remains within acceptable stability margins.

SOP Should Include:

• Definition of excursion thresholds per product
• Decision matrix: acceptable, investigate, or reject
• Chain-of-custody documentation requirements
• CAPA process for root cause and recurrence prevention

Templates for these SOPs can be obtained from Pharma SOPs.

Step 5: Monitor Site Storage and Transportation Conditions:

Site-level deviations can be just as damaging as in-transit excursions.

Best Practices:

• Perform temperature mapping of storage areas
• Use continuous monitoring for refrigerated storage
• Audit site logs during monitoring visits
• Train site staff on logging practices and deviation handling

Include storage assessment in your GMP documentation and trial initiation checklist.

Step 6: Real-Time Monitoring and Analytics:

High-risk routes or time-sensitive biologics may require real-time GPS-linked monitoring devices. These allow for mid-transit intervention.

Capabilities to Consider:

• Live temperature, location, humidity data
• Custom alerts and escalation protocols
• Integration with logistics dashboards and courier platforms
• End-to-end visibility reports for audits

Such systems are key for biologics, vaccines, and ATMP trials.

Step 7: Train All Stakeholders in the Strategy:

Everyone involved—supply planners, QA, depots, couriers, and sites—must understand their role in the risk-based monitoring framework.

Training Should Include:

• How risk tiers are assigned
• When and how loggers are used
• Excursion decision flowcharts
• Documentation and escalation expectations

Step 8: Maintain Regulatory Compliance:

Document your strategy thoroughly to demonstrate compliance with regulatory expectations.

Documents to Maintain:

• Risk-based monitoring strategy SOP
• Product-specific excursion evaluation forms
• Logger qualification certificates
• Monitoring logs and deviation reports

Auditors from agencies like EMA or CDSCO will expect documented justification for reduced or enhanced monitoring levels.

Conclusion:

Risk-based temperature monitoring strategies offer a smart, compliant way to protect the integrity of clinical trial supplies. By assessing product and transit risks, tailoring device use, and training stakeholders, sponsors can ensure both efficiency and regulatory alignment. Whether you’re managing a small investigator-led study or a global adaptive trial, a well-documented and validated risk-based approach is now essential for supply chain excellence.